Semaglutide and lithium: separating the real concern from the rumour

The biggest myth: that semaglutide and lithium simply cannot be combined

The most common misconception floating around online is that lithium and semaglutide are flatly incompatible — a hard stop. That is not what UK prescribing guidance states. The BNF's semaglutide monograph does not list lithium as a contraindicated medicine, and the Wegovy SmPC does not either. What the guidance does flag is that GLP-1 receptor agonists slow gastric emptying, which can alter the absorption timing of other oral medicines taken at the same time. Lithium is one of those medicines where absorption timing and fluid balance both matter.

The practical concern is indirect rather than a direct pharmacological clash. Semaglutide (the active ingredient in Wegovy) does not chemically interfere with lithium's mechanism. The risk runs through a different pathway: nausea, vomiting and diarrhoea are among the most common side effects when starting or increasing the dose, and those symptoms can cause dehydration. Lithium clearance is tightly coupled to sodium and fluid balance. When you lose fluid rapidly, plasma lithium concentration can rise into the toxic range even if the dose of lithium itself has not changed. That is the clinically significant issue, not a direct drug-drug interaction in the traditional sense.

Worth knowing: this is not unique to semaglutide. Any medicine that causes significant GI fluid losses in someone on lithium warrants the same caution. If you want a thorough grounding in how the drug works before going further, our guide to semaglutide dosing and titration explains the step-up schedule and why GI effects are most pronounced in the early weeks, which is when the risk window is widest.

What lithium's narrow therapeutic window means in practice

Lithium is unusual among mood stabilisers because the difference between a therapeutic blood level and a toxic one is small. Clinicians typically aim for a serum lithium level of 0.4–1.0 mmol/L for maintenance (the exact target depends on the indication and the individual). Even modest dehydration can push levels meaningfully above that range. Early signs of lithium toxicity include coarse tremor, confusion, nausea, and muscle twitching, symptoms that overlap with GI side effects of semaglutide, which makes them easy to dismiss or misattribute.

This overlap matters. Someone starting semaglutide who develops nausea and a new hand tremor might reasonably assume it is a semaglutide side effect. It could be. It could also be rising lithium levels. The only way to distinguish them reliably is a blood test. NHS guidance on monitoring lithium is clear that levels should be checked after any significant illness, dietary change, or new medicine that might affect fluid or sodium balance, and starting a GLP-1 medicine qualifies.

If you are already established on lithium and are considering weight management treatment, your psychiatrist or the clinician managing your lithium should be part of the conversation before anything else. This is not bureaucracy for its own sake; it is how the risk is actually managed. For a broader picture of how semaglutide fits into a weight management plan, the semaglutide overview on this site sets out the licensed uses and evidence base clearly.

Practical steps if you are on lithium and want to explore semaglutide

The route forward is straightforward in principle, even if it requires coordination. First, your prescriber needs to know about the lithium. At nume, every consultation is read by a GPhC-registered Independent Prescriber (a real clinician, not software) and declaring all current medicines is part of that process. Lithium will prompt a conversation, not an automatic refusal. Our clinical team's approach is explained on the clinical team page if you want to understand who is reviewing your case.

Second, your lithium levels should be checked at baseline and monitored more frequently in the early months of semaglutide treatment, particularly during dose increases when GI effects tend to peak. NHS guidance on semaglutide recommends telling your prescriber about all other medicines before starting, and this applies with particular force when one of those medicines has a narrow therapeutic window. Whoever prescribes your lithium (whether a GP or a psychiatrist) should receive a notification that you are starting semaglutide.

Third, take dehydration seriously in a way you might not have needed to before. If vomiting or diarrhoea lasts more than 24 hours, contact a clinician rather than waiting it out. Staying well hydrated is always good advice on GLP-1 treatment, but for people on lithium it is especially consequential. Some people also ask whether semaglutide affects other aspects of health beyond weight, and our page covering semaglutide and erectile dysfunction addresses one question that comes up regularly for male patients weighing up the treatment. If you are weighing up the options and costs involved in starting treatment through a private pharmacy, the Wegovy cost guide covers what a legitimate prescription price actually includes. The weight loss treatment overview sets out the broader landscape if you are still at the research stage.

One practical note on what the process looks like if you do proceed: if your consultation is approved, your treatment arrives via DPD tracked delivery, the next working day, in plain packaging, nothing on the outside to indicate what is inside. That matters to a lot of people.

Anyone with questions about how the consultation works, or uncertain whether their current medication list rules them out, can find answers in the site FAQs. For anything more specific, the contact page connects you directly with the team. And if you are ready to take the next step, check your eligibility through a free consultation, a prescriber will assess the full picture, including your lithium, before anything is dispensed.